Research progress on biomarkers related to the efficacy of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
;
(6): 949-954, 2022.
Article
Dans Chinois
| WPRIM
| ID: wpr-956938
ABSTRACT
Esophageal squamous cell carcinoma is one of the most common malignant tumors in China. Neoadjuvant chemoradiotherapy combined with surgery significantly improved the survival rate of locally advanced operable esophageal squamous cell carcinoma, but approximately half of the patients had poor or no efficacy. To accurately predict the efficacy of neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma and select the dominant population of neoadjuvant chemoradiotherapy, many studies on biomarkers have emerged, which have promoted the progress of neoadjuvant therapy for esophageal squamous cell carcinoma to some extent. In this article, the studies on biomarkers predicting the efficacy of neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma were reviewed.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Radiation Oncology
Année:
2022
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS